Roger M Lyons MD F.A.C.P.

Hematology•San Antonio, TX

President Cancer Care Centers of South Texas

Join to View Full Profile

5206 Research DrSan Antonio, TX 78240
Phone+1 210-595-5300
Fax+1 210-614-8740

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 1972 - 1975
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1971 - 1972
University of ManitobaClass of 1967

Certifications & Licensure

TX State Medical License 1975 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2004-2014
Top Doctors:SE Texas Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma Start of enrollment: 2009 Nov 01
Terminated
Phase 2
Study of Ezatiostat (Telintra Tablets) for Treatment of Severe Chronic Neutropenia Start of enrollment: 2009 Apr 01
Terminated
Phase 2
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2009 Nov 01
Completed
Phase 1
Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) Start of enrollment: 2010 Jun 01
Completed
Phase 2
Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts Start of enrollment: 2010 Nov 01
Completed
Phase 3
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant Start of enrollment: 2011 Apr 20
Completed
Phase 3
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA Start of enrollment: 2013 Dec 01
Completed
Phase 2
A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders Start of enrollment: 2014 May 01
Completed
Phase 2
Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients Start of enrollment: 2014 Mar 08
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome.
Guillermo Garcia-Manero, Manila Gaddh, Uwe Platzbecker, R Coleman Lindsley, Sarah M Larson
Annals of Hematology. 2025-03-28
2 citations
ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study.
Michael Maris, Gilles Salles, Won Seog Kim, Tae Min Kim, Roger M Lyons
Targeted Oncology. 2024-05-01
2 citations
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management.
Robert M Rifkin, Saulius K Girnius, Stephen J Noga, Ruemu E Birhiray, Suman Kambhampati
Blood Cancer Journal. 2023-09-19

Abstracts/Posters

Disease and Clinical Characteristics of Patients with Myelofibrosis Enrolled in the MOST Study
Roger M. Lyons, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with N...
Roger M. Lyons, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazo...
Roger M. Lyons, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Roger M Lyons MD F.A.C.P.

Dr. Lyons is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Viewing the full profile is available to verified healthcare professionals only.